Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial

Eli Lilly plans to start Phase 3 trials on a combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year, after the mid-stage trial showed boosted weight loss. The announcement signals progress in the obesity treatment race, with Lilly aiming to expand its portfolio beyond existing injectables.